We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Statins Improve Results of Vascular Surgery

By HospiMedica International staff writers
Posted on 10 Dec 2008
A new study demonstrates that lipid-lowering therapies could stabilize coronary plaques and improve vascular surgery postoperative outcome. More...


Researchers at the Erasmus Medical Center (EMC; Rotterdam, The Netherlands) hypothesized that this effect was anti-inflammatory in nature, as opposed to an effect directly related to the statin's lipid-lowering efficacy. To test this conjuncture, they conducted a double blind, placebo-controlled trial, in which statin-naive patients were randomly assigned to receive either 80 mg of extended release fluvastatin or a matched placebo, starting 37 days prior to surgery; a total of 250 patients were assigned to fluvastatin and 247 to placebo. To assess the influence on inflammation markers by statin therapy interleukin-6 (IL-6) and C-reactive protein (CRP) were measured at randomization and immediately prior to surgery.

The study results showed that IL-6 and CRP concentrations remained stable in the placebo group and decreased in the fluvastatin group. The incidence of myocardial infarction (MI) in the fluvastatin and placebo allocated groups was 10.8% compared to 19%, and the incidence of the composite cardiac death and MI was 4.8% compared to 10.2%, respectively. The study was presented at the Veith Symposium, held in New York (NY, USA) during November 2008.

"Fluvastatin therapy was associated with a reduction of inflammation activity and improved postoperative cardiac outcome in elective vascular surgery patients," concluded study presenter Professor Don Poldermans, M.D., and colleagues at the Erasmus Medical Center.

Statins form a class of hypolipidemic drugs used to lower cholesterol levels in people with or at risk of cardiovascular disease. They lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting enzyme of the mevalonate pathway of cholesterol synthesis. Inhibition of this enzyme in the liver stimulates low-density lipoprotein (LDL) receptors, resulting in an increased clearance of LDLs from the bloodstream and a decrease in blood cholesterol levels. The first results can be seen after one week of use and the effect is maximal after four to six weeks.

Related Links:
Erasmus Medical Center



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
X-Ray Generator
Advantage Plus Generators
New
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The method uses data streams commonly available on consumer wearables, including heart rate, physical activity, and oxygen saturation (photo courtesy of 123RF)
Image: The method uses data streams commonly available on consumer wearables, including heart rate, physical activity, and oxygen saturation (photo courtesy of 123RF)

Wearable AI Tool Predicts Hospitalization Risk in Heart Failure

Heart failure, a condition in which the heart cannot pump enough blood to meet the body’s needs, is a leading driver of unplanned hospital use. Clinicians often lack continuous insight into symptom changes... Read more

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.